The role of leptin in the pathogenesis of obesity has been intensively studied in recent years [1] . Many studies in obese patients found an apparent discrepancy between circulating leptin levels and leptin effects, suggesting that leptin resistance might be a common phenomenon in obese individuals [1] . The mechanisms causing leptin resistance are not, however, clear. Structural defects of the leptin receptor, associated with a loss of function which might cause cellular leptin resistance, do not seem to be a common cause in human beings [2] indicating that abnormalities in postreceptor signalling elements, either genetically determined or caused by regulatory mecha- Diabetologia (2001) Abstract Aims/hypothesis. Leptin resistance in obese humans seems to be predominantly caused by signalling abnormalities at the post receptor level. Leptin resistance in obese individuals is frequently associated with insulin resistance and pronounced hyperinsulinaemia indicating a negative crosstalk of the insulin and leptin signalling chain.
nisms, could have a part to play. A negative crosstalk of the insulin and the leptin signalling chain seems a possible regulatory mechanism as most obese individuals have insulin resistance and hyperinsulinaemia. We aimed to investigate whether an interference of insulin and leptin signalling can be found in isolated cells and to identify potential molecular mechanisms of a possible crosstalk.
Leptin signalling is mediated by ligand-induced conformational changes of the leptin receptor which activates the intracellular signal transducing protein janus kinase-2 (JAK-2) [3, 4] . JAK-2 has intrinsic tyrosine kinase activity causing autophosphorylation and subsequently phosphorylation of the leptin receptor on different tyrosine residues [5, 6] . Downstream of JAK-2 activation of a signalling cascade similar to that of the insulin receptor occurs, e. g. phosphorylation of signal transducer and activator of transcription (STAT) proteins as well as insulin receptor substrate-1 and ±2 (IRS-1, IRS-2) [7±11]. This allows molecular candidates to be identified which might connect both signal transduction pathways and might mediate a negative crosstalk.
Leptin resistance is discussed both in terms of the hypothalamic action of leptin as well as of peripheral leptin effects. It is not clear whether the peripheral hyperinsulinaemia found in obese individuals might lead to high insulin concentrations in the hypothalamus. By contrast, high local insulin concentrations in peripheral tissues, in particular in the islets of the pancreas, are very likely as chronic oversecretion is typically found in obese people. Moreover, modulation of insulin secretion by leptin in human islets has been found [12±14] . Therefore, the human beta cell is probably a target of extracranial leptin action and insulin-secreting cell lines might reflect to some extent the situation in beta cells. We used the insulin-secreting cell line RINr 1046±38 to test whether insulin interferes with the action of leptin. Our data suggest that supraphysiological insulin concentrations could induce leptin resistance in insulin-secreting cells. Our studies from transfected cell lines show that this insulin-induced leptin resistance could be due to inhibition of JAK-2 phosphorylation by a tyrosine phosphatase-dependent pathway.
Materials and methods
Materials. Cell culture reagents and fetal calf serum were purchased from Gibco (Eggenstein, Germany). Human insulin and murine recombinant leptin were provided by Hoechst AG (Frankfurt, Hessen, Germany). [g 32 P]ATP (3000 Ci/ mmol) was from DuPont NEN (Bad Homburg, Hessen, Germany) and L-a-phosphatidylinositol from Sigma (Munich, Germany). Polyclonal antibodies against JAK-2 were purchased from Upstate Biotechnology (Lake Placid, N. Y., USA); polyclonal IRS-1 and IRS-2 antibodies were kindly provided by M. F. White (Boston, Mass., USA), monoclonal antiphosphotyrosine antibody (PY20) was from Leinco (Ballwin, USA) and protein A sepharose from Pharmacia (Uppsala, Sweden). The reagents for SDS/PAGE and immunoblotting were purchased from Roth (Karlsruhe, Germany) and BioRad (Munich, Germany). Nitrocellulose was from Schleicher and Schuell (Dassel, Germany) and the non-radioactive enhanced chemiluminescence detection system (ECL) was obtained from Amersham (Braunschweig, Germany). The rat insulin RIA Kit (RI 13K) was purchased from Linco (St. Charles, Mo. USA).
Measurement of insulin release in RINr 1046±38 cells. RIN 1046±38 cells were plated (3´10 4 cells per well) into 24-well microtitre plates (Falcon, Fortworth, Tex., USA) and grown [15, 16] . Endogenous expression of the long leptin receptor, IRS-1, IRS-2, JAK-2, SHP1 and SHP2 could be shown for RINr 1046±38 cells by RT-PCR analysis (data not shown). After the cells reached 50 % confluency, they were washed in Krebs±Ringer HEPES buffer and starved for 60 min in the same buffer containing 1 mmol/l glucose and 0.1 % bovine serum albumin. The cells were then incubated with insulin (1 nmol/l insulin for 4 h), the insulin containing buffer was removed and the cells were washed two times with Krebs±Ringer HEPES buffer. Subsequently, cells were stimulated with 60 ng/ ml leptin for 30 min. or glucose (3 mmol/l, 30 min.) in Krebs±Ringer HEPES buffer containing 1 mmol/l glucose and 0.1 % bovine serum albumin. The supernatant was then collected to determine insulin release. To measure intracellular insulin content, cells were washed two times with Krebs±Ringer HEPES buffer and then lysed overnight with a solution containing 150 ml absolute ethanol, 47 ml H 2 O and 3 ml 10 N HCl at 4 C. Insulin measurement from cell supernatant and lysates was done by a RIA Kit (Linco, RI 13K).
Transient expression in HEK 293 cells. Human embryonic kidney fibroblast 293 cells were grown in Dulbecco's MEM/Nutrient Mix F12 medium supplemented with 10 % fetal calf serum. Cells were transfected according to the protocol of Chen and Okayama [17] . Briefly, cells were grown in 6-well dishes at a density of 3´10 5 cells per well in 2 ml of DMEM medium. A total of 4 mg supercoiled plasmid DNA was mixed with 0.25 mol/l CaCl 2 in a final volume of 0.1 ml. To this an equal amount of 2 transfection buffer (50 mmol/l BES, pH 6.95, 280 mmol/l NaCl, 1.5 mmol/l Na 2 HPO 4 ) was added and after incubation for 10 min at room temperature, the mixture was given dropwise to the cells. After incubation for 16 h at 37 C and 3 % CO 2 the cells were serum starved for 24 h in DMEM (1 g/l glucose) containing 0.5 % fetal calf serum.
Assay of phosphatidylinositol-3 kinase activity. After incubation with 100 nmol/l insulin for 10 min or with 10 ng/ml recombinant leptin for 15 min, cells were rinsed once with ice cold PBS and lysed at 4 C for 5 min in 1 ml of lysis buffer (50 mmol/l HEPES pH 7.2, 150 mmol/l NaCl, 1 mmol/l EGTA, 10 % (v/v) glycerol, 1 % (v/v) Triton X-100, 100 mmol/l NaF, 10 mmol/l sodium pyrophosphate, 100 mmol/l sodium orthovanadate, 1 mmol/l PMSF, 10 mg/ml aprotinin). Lysates were centrifuged at 13 000´g for 10 min and the supernatants were immunopurified with the indicated antibody after dilution of Triton X-100 to 0.4 %. The immunocomplexes were absorbed to protein A Sepharose for 2 h. Immunoprecipitates were washed three times and pellets were directly incubated with L-a phosphatidylinositol (0.1 mg/ml) for 10 min in a solution containing 50 mmol/l [g 32 P]ATP, 1.2 mmol/l Na-orthovanadate, 5 mmol/l MgCl 2 , 25 mmol/l HEPES, pH 7.4, at room temperature for 10 min in a final volume of 50 ml. After addition of 20 ml 8 mol/l HCl, lipids were extracted with 160 ml chloroform/methanol (1:1, by vol), centrifuged at 13 000´g for 5 min and the lower phase containing the phospholipids was lyophilised and subsequently dissolved in 5 ml chloroform/ methanol (1:1, by vol). The products of the reaction were separated by thin layer chromatography [9] . 32 P-labelled phospholipids were detected by autoradiography. Standard lipids were run in parallel and detected with iodine vapour.
SDS polyacrylamide gel electrophoresis and immunoblotting.
Transiently transfected HEK 293 cells and Rat-1 fibroblasts stably transfected with the human insulin receptor were serum depleted and stimulated as indicated in the Figures. Cells were then washed once with ice-cold PBS and lysed in a buffer containing protease and phosphatase inhibitors (20 mmol/l HE-PES, 150 mmol/ NaCl, 10 % glycerol, 1 % Triton-X-100, 1.5 mmol/l MgCl 2 , 4 mmol/l EGTA, 1 mmol/ EDTA, 1200 TIU/L aprotinin, 10 mmol/l Na 4 P 2 O 7 , 2 mmol/l Na-orthovanadate, 100 mmol/l NaF, 2 mmol/l PMSF, pH 7.4). The lysates were centrifuged at 13 000´g for 10 min. After addition of Laemmli buffer, samples were applied to a 7.5 % SDS/polyacrylamide gel. Proteins were then transferred to nitrocellulose filters by semi-dry blotting (transfer buffer: 20 mmol/l NaH 2 PO 4 , 20 mmol/l Na 2 HPO 4 , pH 8.8). Filters were blocked with NET buffer (150 mmol/l NaCl, 5 mmol/l EDTA, 50 mmol/l TRIS, 0.05 % Triton X-100 and 0.25 % gelatine, pH 7.4) for 1 h. Subsequently, filters were incubated with the first antibody overnight at 4 C. The membranes were washed three times with NET buffer before they were incubated with peroxidase-conjugated anti-mouse or anti-rabbit IgG for 1 h at room temperature. Visualisation of immunocomplexes was done by enhanced chemiluminescence (ECL, Amersham).
Statistical analysis. For statistical analysis Students t test was applied and a p value of less than 0.05 was considered statistically significant.
Results
In this study we tested the hypothesis that leptin resistance might be aggravated by a negative crosstalk of the insulin signalling chain. We used the glucose sensitive insulinoma cell line RINr 1046±38 to evaluate whether high insulin concentrations can alter leptin effects on insulin secretion. Leptin treatment (60 ng/ml, 30 min) stimulated insulin secretion by 35 6.3 % (n = 10, p < 0.001). Activation of insulin secretion by leptin was similar to that of 3 mmol/l glucose (Fig. 1) . Preincubation of these cells with insulin (1 nmol/l, 4 h) could cancel the action of leptin. As a control, insulin incubation for 4 h alone had no substantial effect on insulin secretion. This therefore suggests that high insulin concentrations interfere with leptin signal transduction in insulin-secreting cells. The insulinoma cell line RINr 1046±38, which we studied, contains low amounts of insulin and leptin signal transduction proteins and is therefore not suitable for addressing the mechanism of a crosstalk between the insulin and leptin signalling pathway. We used instead HEK293 cells which express the long isoform of the leptin receptor and the PI 3-kinase [9] . To ensure that the signalling proteins which were overexpressed during the course of our study in HEK293 cells are also expressed in RINr 1046±38 cells, we performed polymerase chain reaction and confirmed the presence of the corresponding mRNAs (data not shown).
To study insulin and leptin-stimulated PI 3-kinase activity the signal-transducing proteins JAK-2 and IRS-2 were transiently overexpressed in HEK 293 cells because both signalling elements were important for leptin stimulated PI 3-kinase activation [9] . HEK 293 cells were starved and stimulated with leptin or insulin. Whole cell lysates were immunoprecipitated with JAK-2 antibodies and the immunocomplexes, coupled to Sepharose beads, were subjected to PI 3-kinase assay. In HEK 293 cells overexpressing JAK-2 and IRS-2 as intracellular signalling proteins, leptin but not insulin was able to stimulate JAK-2-associated PI 3-kinase activity by 2.1 0.46-fold (Fig. 2 , left side, n = 3). To investigate whether the insulin signal interferes with the action of leptin on PI 3-kinase we transfected HEK 293 cells with JAK-2, IRS-2 and HIR. Co-overexpression of the human insulin receptor (HIR) abolished the effect of leptin on the PI 3-kinase which can be seen in Figure 2 (right side). In addition, preincubation with insulin (1 nmol/l, 4 h) reduced leptin-stimulated and JAK-2-associated PI 3-kinase activity in the absence of insulin receptor overexpression (lower part of Figure 2 ), again suggesting that the insulin signal interferes with leptin-stimulated PI 3-kinase.
We then studied whether insulin is also able to reduce leptin-stimulated JAK-2 phosphorylation up- Fig. 1 . RINr 1046±38 cells were plated into 24-well microtitre plates and grown until they reached 50 % confluency. Cells were starved for 60 min. and then incubated for 4 h with or without 1 nmol/l insulin in Krebs±Ringer HEPES buffer with 1 % bovine serum albumin. Insulin was washed off before stimulation with 60 ng/ml leptin for 30 min. or glucose (3 mmol/l, 30 min.) in Krebs±Ringer HEPES buffer containing 1 % bovine serum albumin and 1 mmol/l glucose. After that time the buffer was collected for determination of insulin release. For the measurement of intracellular insulin content the cells were lysed as described in the methods. (Student's t test, *p < 0.001) stream of PI 3-kinase. HEK 293 cells were transiently transfected with JAK-2 and in analogy to the RIN 1046±38 experiment preincubated with insulin (1 nmol/l, 4 h) and subsequently stimulated with leptin (60 ng/ml, 30 min). Proteins of whole cell lysates were separated by SDS-PAGE and transferred to nitrocellulose. JAK-2 phosphorylation was detected by immunoblotting with anti-phosphotyrosine antibodies (upper panel of Figure 3 ). To ensure that similar amounts of proteins were expressed, the nitrocellulose filter was reblotted with JAK-2 antibody (lower panel of Figure 3 ). Transient expression of JAK-2 in HEK 293 cells caused tyrosine phosphorylation already in the basal state which is in agreement with other reports [18, 19] . This JAK-2 phosphorylation could be further increased by leptin stimulation by 2.06 0.54-fold (n = 3, p < 0.05). Preincubation of HEK 293 cells with insulin, however, abolished the effect of leptin on JAK-2 phosphorylation which suggests that insulin interferes with the action of leptin even at the level of JAK-2.
To clarify if this insulin-induced cellular leptin resistance is mediated by the insulin receptor signalling network, we tested whether overexpression of the insulin receptor reduced JAK-2 phosphorylation in HEK 293 cells. Co-overexpression of JAK-2 with the human insulin receptor could reduce basal JAK-2 phosphorylation (Fig. 4) . This effect was more pronounced with increased expression of the insulin receptor suggesting that the insulin signalling network is involved in reduced JAK-2 phosphorylation. To find out if this effect is specific for the insulin receptor, we co-overexpressed the EGF-and the PDGF receptor with JAK-2. Whole cell lysates were subjected to SDS-PAGE and subsequently immunoblotted with anti-phosphotyrosine antibodies. We measured autophosphorylation of the different tyrosine kinase receptors and that of JAK-2 (Fig. 5) . In contrast to the human insulin receptor, the PDGF-receptor was not able to reduce tyrosine phosphorylation of JAK-2. After overexpression of the EGF receptor JAK-2 phosphorylation was slightly reduced (40 12 % inhibition, n = 3) but the insulin receptor was much Fig. 2 shows JAK-2-associated PI 3-kinase activity from HEK 293 cells overexpressing JAK-2 and IRS-2 which were preincubated with or without 1 nmol/ l insulin for 4 h before leptin stimulation (10 ng/ml, 15 min). Whole cell lysates were incubated with anti-JAK-2 antibodies. PI 3-kinase was assayed in the immunoprecipitates and 32 P-incorporation into phosphatidylinositol was visualized by separation of the labelled phospholipids on thin layer chromatography plates and autoradiography Fig. 3 . HEK 293 cells overexpressing JAK-2 were preincubated with or without insulin (4 h, 1 nmol/l) and then stimulated with leptin (30 min, 60 ng/ml) at 37 C. Whole cell lysates were prepared, proteins were separated by SDS-PAGE, transferred to nitrocellulose and blotted with antibodies detecting phosphotyrosine (ptyr). To prove that similar amounts of protein were overexpressed the filters were reblotted with antibodies against JAK-2 (lower part) Fig. 4 . The effect of co-overexpression of different amounts of the human insulin receptor together with JAK-2 was tested. HEK 293 cells were transiently transfected with different amounts of insulin receptor DNA (0±1 mg/ml) together with or without JAK-2 (1 mg/ml) as indicated. Cells were stimulated with 100 nmol/l insulin for 5 min at 37 C. Whole cell lysates were prepared, the proteins were separated by SDS-PAGE, transferred to nitrocellulose and blotted with anti-phosphotyrosine antibodies to detect tyrosine phosphorylation of JAK-2 and the insulin receptor (IR). Filters were reblotted with anti-JAK-2 antibodies to detect the overexpressed protein level (lower panel) more active (82 21 % inhibition, n = 7) than the EGF receptor. Thus, the reduction of JAK-2 phosphorylation in HEK 293 cells seems to be specific to the insulin receptor signal.
To rule out unspecific protein interaction after transient transfection in HEK 293 cells, we studied rat-1 fibroblasts which were stably transfected with the human insulin receptor (rat-1 HIR). Endogenous JAK-2 expression and phosphorylation was detected after immunoprecipitation with polyclonal JAK-2 antibodies. JAK-2 could be visualized by immunoblotting with JAK-2 antibodies (Fig. 6) . Phosphorylation of JAK-2, detected by reblotting of the same nitrocellulose with an anti-phosphotyrosine antibody, could be found even in the unstimulated state. Insulin reduced the phosphorylation of JAK-2 only in insulin receptor overexpressing rat-1 cells. This suggests again that the reduction of JAK-2 phosphorylation was induced by the insulin receptor signal.
Enzymes with the potential to reduce JAK-2 phosphorylation are the phosphatases SHP-1 and SHP-2 because both are associated with JAK-2 and can be activated by the insulin receptor [20] . Furthermore, evidence is given that both phosphatases can associate with JAK-2 which may result in activation of the catalytic domain [18, 21] . SHP-2 has also been shown to bind to the phosphorylated leptin receptor which inhibits JAK-2 phosphorylation [5, 6] . Therefore, we investigated if SHP-1 or SHP-2 can mediate the effect of the insulin signal on JAK-2 phosphorylation in HEK 293 cells. Overexpression of JAK-2 alone and together with the active or inactive form of the tyrosine phosphatases SHP-1 or SHP-2 was performed. Immunoblot analysis showed that overexpression of SHP-1 induced JAK-2 dephosphorylation to a similar degree as the insulin receptor (84 25 %, n = 6, p < 0.05). This was confirmed by the expression of a catalytically inactive form of SHP-1 which hardly inhibited JAK-2 phosphorylation ( Figure 7) . In contrast, SHP-2 was much less able to provoke dephosphorylation of JAK-2 after overexpression in HEK 293 cells. Tyrosine phosphorylation of SHP-1 by JAK-2 can only be observed with the catalytically negative SHP-1 which is not able to auto-dephosphorylate. In contrast to SHP-1, we were not able to detect tyrosine phosphorylation of SHP-2 in our experimental setting. 5 . HEK 293 cells were transfected as indicated. PRK5, expression vector,; JAK-2, janus kinase-2,; HIR, human insulin receptor,; PDGF-R, platelet derived growth factor receptor,; EGF-R, epidermal growth factor receptor. Cells were stimulated for 5 min with 100 nmol/l insulin, EGF or PDGF. Whole cell lysates were prepared, the proteins were separated by SDS-PAGE, transferred to nitrocellulose and blotted with antiphosphotyrosine. The positions of JAK-2, PDGF-R, EGF-R and HIR are indicated by arrows Fig. 6 A, B . Parental rat-1 fibroblasts (Rat-1) and cells stably overexpressing the human insulin receptor (Rat-1 HIR) were stimulated with 100 nmol/l insulin for 5 min at 37 C. Cells were lysed and proteins were immunoprecipitated with JAK-2 antibody. Immunoprecipitates were washed and separated by SDS-PAGE. Proteins were transferred to nitrocellulose filters which were blotted either with anti-JAK-2 antibodies (A) or with anti-phosphotyrosine antibodies (B) Fig. 7 . Total cell lysates of HEK 293 cells overexpressing JAK-2 alone or together with the human insulin receptor (HIR) or the tyrosine phosphatases SHP-1 and SHP-2 in its active or catalytically inactive (*) form were applied to SDS-PAGE. As a control the PRK5 vector was transiently transfected. After SDS-PAGE, proteins were transferred to nitrocellulose and blotted with phosphotyrosine antibodies (upper panel). The presence of similar amounts of protein was verified by reprobing the nitrocellulose with JAK-2 antibodies (lower panel)
Because SHP-1 could dephosphorylate JAK-2 in HEK 293 cells, we assessed if the inhibitory effect of the insulin receptor on JAK-2 was mediated by SHP-1. Studies were done in HEK 293 cells overexpressing JAK-2, the insulin receptor and a catalytically inactive form of SHP-1. In addition, overexpression of catalytically inactive SHP-2 was used as a control. The catalytically inactive form of SHP-1 could partially prevent the effect of the insulin receptor on JAK-2 phosphorylation but SHP-2 had no major effect on JAK-2 dephosphorylation provoked by the insulin receptor (Fig. 8) .
Discussion
To address the question of a cross talk between leptin-and insulin signalling pathways, we studied the effects of leptin on insulin secretion as well as the consequences of pretreatment of cells with insulin. In addition we used HEK293 cells as model systems to follow the interaction of specific proteins. The data obtained in the insulin-secreting cell lines suggest that insulin could negatively regulate leptin signalling. Effects of leptin on insulin-secreting cells have been described by many investigators [12, 13, 22±32] and the majority of these in-vitro studies suggest that leptin inhibits insulin secretion [12, 13, 22±30] . This conclusion, however, is in conflict with in vivo data from obese individuals. Despite high leptin levels hypersecretion of insulin and hyperinsulinaemia is found in obese humans. Preincubation of RINr 1046±38 cells with high insulin levels completely cancelled the effect of leptin on insulin secretion. This suggests that the insulin signalling pathway could interfere with leptin signalling and could cause leptin resistance in insulin-secreting cells. It is not clear if analogous effects could be induced in different cell models reflecting other target tissues of leptin action. Furthermore insulin concentrations used do not reflect the physiological in-vivo situation. We tested the effects of insulin at a concentration of 1 nmol/l which exceeds the concentrations circulating in obese individuals. Therefore, extrapolation of our data to the in vivo situation in peripheral target tissues of leptin action and in particular to the hypothalamus might not be appropriate. However, a different situation might exist for the pancreatic beta cell because very high local levels of insulin are reached in the islets of individuals who are in a state of chronic hypersecretion [33] .
Our data from insulinoma cells indicate that hyperinsulinaemia itself could cause or aggravate leptin resistance in an autocrine way if very high insulin concentrations are reached in local islets [33] . Our data agrees with studies on mice lacking the insulin receptor or insulin receptor substrate-1 in pancreatic beta cells [34, 35] . In these animal models, interruption of the insulin signalling pathway in beta cells resulted in failure of glucose-dependent insulin secretion as well as lower fat mass and leptin. This suggests that mice which are defective in insulin signalling of peripheral tissues are more sensitive towards the action of leptin.
Our studies in HEK 293 and rat-1 cells show that insulin could interfere with leptin signalling at the level of JAK-2. We found reduced leptin-dependent phosphorylation of JAK-2 after incubation with high insulin concentrations. Our data suggest that this effect of insulin is mediated, at least partly, by the phosphatase SHP-1. There is evidence that the homologous tyrosine phosphatases SHP-1 and SHP-2 associate with JAK-2 as well as with the insulin receptor [18, 21, 36, 37] . Association of SHP-1 with the insulin receptor occurs at the C-terminal region of SHP-1 and results in phosphorylation of SHP-1 on tyrosine 538 which could activate the phosphatase [36] . Moreover, the N-terminal region of SHP-1 can interact with JAK-2 [18] . A direct association of SHP-1 with JAK-2 caused activation of the phosphatase and subsequent dephosphorylation of JAK-2 [18] . In addition, inhibition of leptin-induced JAK-2 phosphory- Fig. 8 . The impact of the tyrosine phosphatases SHP-1 and SHP-2 on the inhibitory effect of insulin on JAK-2 phosphorylation was tested. HEK 293 cells were transfected with the PRK5 vector (left side), with JAK-2 alone or together with the human insulin receptor expression plasmid with or without a catalytically inactive (*) SHP-1 or SHP-2. Cells were stimulated with 100 nmol/l insulin for 5 min at 37 C. Whole cell lysates were prepared, the proteins were separated by SDS-PAGE, transferred to nitrocellulose and blotted with antibodies against phosphotyrosine to detect tyrosine phosphorylation of JAK-2 and the insulin receptor b-subunit (HIR). Filters were reblotted with JAK-2, SHP-2 and SHP-1 antibodies (lower panel) to measure the amount of overexpressed proteins lation by SHP-2 has been reported [5, 6] . SHP-2 was activated upon leptin stimulation and reduced JAK-2 phosphorylation and STAT3-mediated gene induction [5, 6] . A negative feedback of the leptin signal through activation of SHP-2 could therefore be possible. We have now shown that SHP-1 could also lead to JAK-2 dephosphorylation. A potential model for the insulin signalling pathway leading to reduced JAK-2 phosphorylation is given in Figure 9 .
In summary, our data suggest that high insulin levels can induce leptin resistance in RINr 1046±38 cells. We investigated possible molecular mechanisms for this effect in HEK 293 cells and rat-1 fibroblasts. Our studies suggest that the insulin signal interferes with JAK-2 phosphorylation and that SHP-1 is, at least partly involved in the negative effect of the insulin receptor on JAK-2. Therefore, hyperinsulinaemia in obese individuals could lead to an aggravation of leptin resistance by this molecular mechanism. In this case high insulin levels would be positively correlated with leptin levels independent of the body weight. This has already been shown by some investigators [38±40] but it is not clear whether a cycle of hyperinsulinaemia-induced peripheral leptin resistance with insufficient suppression of pancreatic insulin release really exists in obese patients. 
